AIM: To investigate the role of functional genetic polymorphisms of metabolic enzymes of tobacco carcinogens in the development of colorectal adenomas. METHODS: The study subjects were 455 patients with colorectal adenomas and 1052 controls with no polyps who underwent total colonoscopy in a preretirement health examination at two Self Defense Forces hospitals. The genetic polymorphisms studied were CYP1A1 2A (rs 4646903), CYP1A1 2C (rs 1048943), GSTM1 (null or non-null genotype), GSTT1 (null or non-null genotype) and NQO1 C609T (rs 1800566). Genotypes were determined by the polymerase chain reaction (PCR)-restriction fragment length polymorphism or PCR method using genomic DNA extracted from the buffy coat. Cigarette smoking and other lifestyle factors were ascertained by a self-administered questionnaire. The associations of the polymorphisms with colorectal adenomas were examined by means of OR and 95%CI, which were derived from logistic regression analysis. Statistical adjustment was made for smoking, alcohol use, body mass index and other factors. The gene-gene interaction and effect modification of smoking were evaluated by the likelihood ratio test. RESULTS: None of the five polymorphisms showed a significant association with colorectal adenomas, nor was the combination of GSTM1 and GSTT1. A borderline significant interaction was observed for the combination of CYP1A1 2C and NQO1 (P = 0.051). The OR associated with CYP1A1 2C was significantly lower than unity among individuals with the NQO1 609CC genotype. The adjusted OR for the combination of the CYP1A1 2C allele and NQO1 609CC genotype was 0.61 (95%CI: 0.42-0.91). Although the interaction was not statistically significant (P = 0.24), the OR for individuals carrying the CYP1A1 2C allele and GSTT1 null genotype decreased significantly compared with those who had neither CYP1A1 2C allele nor GSTT1 null genotype (adjusted OR: 0.69, 95%CI: 0.49-0.97). Smoking did not modify the associations of the individual polymorphisms with colorectal adenomas. There was no measurable effect modification of smoking even regarding the combination of the genetic polymorphisms of the phase I and phase II enzymes. CONCLUSION: Combination of the CYP1A1 2C and NQO1 609CC genotypes was associated with a decreased risk of colorectal adenomas regardless of smoking status.
AIM: To investigate the role of functional genetic polymorphisms of metabolic enzymes of tobacco carcinogens in the development of colorectal adenomas. METHODS: The study subjects were 455 patients with colorectal adenomas and 1052 controls with no polyps who underwent total colonoscopy in a preretirement health examination at two Self Defense Forces hospitals. The genetic polymorphisms studied were CYP1A1 2A (rs 4646903), CYP1A1 2C (rs 1048943), GSTM1 (null or non-null genotype), GSTT1 (null or non-null genotype) and NQO1C609T (rs 1800566). Genotypes were determined by the polymerase chain reaction (PCR)-restriction fragment length polymorphism or PCR method using genomic DNA extracted from the buffy coat. Cigarette smoking and other lifestyle factors were ascertained by a self-administered questionnaire. The associations of the polymorphisms with colorectal adenomas were examined by means of OR and 95%CI, which were derived from logistic regression analysis. Statistical adjustment was made for smoking, alcohol use, body mass index and other factors. The gene-gene interaction and effect modification of smoking were evaluated by the likelihood ratio test. RESULTS: None of the five polymorphisms showed a significant association with colorectal adenomas, nor was the combination of GSTM1 and GSTT1. A borderline significant interaction was observed for the combination of CYP1A1 2C and NQO1 (P = 0.051). The OR associated with CYP1A1 2C was significantly lower than unity among individuals with the NQO1 609CC genotype. The adjusted OR for the combination of the CYP1A1 2C allele and NQO1 609CC genotype was 0.61 (95%CI: 0.42-0.91). Although the interaction was not statistically significant (P = 0.24), the OR for individuals carrying the CYP1A1 2C allele and GSTT1 null genotype decreased significantly compared with those who had neither CYP1A1 2C allele nor GSTT1 null genotype (adjusted OR: 0.69, 95%CI: 0.49-0.97). Smoking did not modify the associations of the individual polymorphisms with colorectal adenomas. There was no measurable effect modification of smoking even regarding the combination of the genetic polymorphisms of the phase I and phase II enzymes. CONCLUSION: Combination of the CYP1A1 2C and NQO1 609CC genotypes was associated with a decreased risk of colorectal adenomas regardless of smoking status.
Authors: Christoph Sachse; Gillian Smith; Murray J V Wilkie; Jennifer H Barrett; Robin Waxman; Frank Sullivan; David Forman; D Timothy Bishop; C Roland Wolf Journal: Carcinogenesis Date: 2002-11 Impact factor: 4.944
Authors: H Inoue; C Kiyohara; S Shinomiya; T Marugame; E Tsuji; K Handa; H Hayabuchi; H Eguchi; Y Fukushima; S Kono Journal: Cancer Lett Date: 2001-02-26 Impact factor: 8.679
Authors: H Inoue; C Kiyohara; T Marugame; S Shinomiya; E Tsuji; K Handa; H Hayabuchi; K Onuma; H Hamada; H Koga; S Kono Journal: Cancer Res Date: 2000-07-15 Impact factor: 12.701
Authors: Edine W Tiemersma; Annelies Bunschoten; Frans J Kok; Hansruedi Glatt; Sybrand Y de Boer; Ellen Kampman Journal: Int J Cancer Date: 2004-01-01 Impact factor: 7.396
Authors: Evropi Theodoratou; Zahra Montazeri; Steven Hawken; Genevieve CdL Allum; Jacintha Gong; Valerie Tait; Iva Kirac; Mahmood Tazari; Susan M Farrington; Alex Demarsh; Lina Zgaga; Denise Landry; Helen E Benson; Stephanie H Read; Igor Rudan; Albert Tenesa; Malcolm G Dunlop; Harry Campbell; Julian Little Journal: J Natl Cancer Inst Date: 2012-09-26 Impact factor: 13.506
Authors: Le Du; Lei Lei; Xiaojuan Zhao; Hongjuan He; Erfei Chen; Jing Dong; Yuan Zeng; Jin Yang Journal: J Cancer Date: 2018-04-06 Impact factor: 4.207